Dr. Steven Neema Seyedin, MD

Dr. Seyedin practices at UCSF Helen Diller Medical Center at Parnassus Heights in San Francisco, California, part of University of California Health.

Dr. Seyedin's NPI, 1134513450, was assigned on March 25, 2015. Dr. Seyedin graduated from David Geffen School of Medicine at UCLA in 2014. Dr. Seyedin holds California license A169076.

Dr. Seyedin's primary practice is UCSF Helen Diller Medical Center at Parnassus Heights, at 505 Parnassus Ave, Box 0296, San Francisco, CA 94143 in San Francisco County. The practice phone is (415) 353-2733.

Dr. Seyedin's primary practice is UCSF Helen Diller Medical Center at Parnassus Heights in San Francisco, California, part of University of California Health. Dr. Seyedin is also affiliated with Zuckerberg San Francisco General Hospital and Trauma Center. The medical group on file is UCSF Pediatrics. Dmand AI also links Dr. Seyedin to 2 more hospitals, 4 medical groups and 3 group practices and clinics, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Seyedin practices, 7 sites in all. Vendor and product names are available with a free account.

Radiation oncology is Dr. Seyedin's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dr. Seyedin is board certified in radiation oncology by the American Board of Radiology. Dmand AI has Dr. Seyedin's licenses on file in 3 states: California, Iowa and Illinois.

Dmand AI lists anal cancer radiation, bladder cancer radiation, bone cancer radiation, cancer radiation-upper GI, colorectal cancer radiation, head & neck cancer radiation, lung cancer radiation and pancreatic cancer radiation among the conditions Dr. Seyedin treats.

CMS data shows 1,757 Medicare services from Dr. Seyedin across 14 procedure codes in 2024, for 293 Medicare patients. Medicare paid $149,845 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 293 Medicare patients who saw Dr. Seyedin in 2024. The largest group is 65 to 74, with 151 patients. 75% of them have cancer, and 75% have high blood pressure. 27% are also on Medicaid. Their average risk score is 1.90, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Seyedin's median patient age at 72, with 6% women.

In 2024, Dr. Seyedin wrote 156 Medicare Part D claims for 67 patients. 95% of them were for generic drugs. CMS names the drug for 102 of them, across 3 drugs with 11 or more claims each, at $2,691 in total drug cost. In 2023, CMS named 118 claims across 3 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Seyedin for performance year 2024, reported through an alternative payment model (APM). Dr. Seyedin accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Seyedin as offering telehealth.

Dmand AI links 47 papers to Dr. Seyedin, published from 2010 to 2025. 2024 was the busiest year, with 6. The most frequent topics are Chemoradiotherapy, Neoplasm Metastasis and Antibodies, Monoclonal. Dr. Seyedin has published most often in Adv Radiat Oncol. Dr. Seyedin's most frequent co-authors are James William Welsh, MD, Jeremy Phillip Harris, MD and Joseph Caster, MD.

Dmand AI links Dr. Seyedin to 1 clinical trial. 1 is still active or recruiting. Conditions studied include Prostatic Neoplasms and Prostatic Diseases.

CMS Open Payments shows 16 general payments to Dr. Seyedin from 10 drug and device companies from 2021 to 2025. Food and beverage make up the largest share, 100% of the total. RefleXion Medical, Inc. paid the most, $322.

Dr. Seyedin graduated from David Geffen School of Medicine at UCLA in 2014. Dr. Seyedin is a member of ASTRO, ASCO and RSNA.

Dr. Seyedin is in network with 13 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 8. Check the plan with the practice before a visit.